Advertisement

Psychopharmacology

, Volume 59, Issue 3, pp 293–297 | Cite as

Anticonvulsant action of cannabis in the rat: Role of brain monoamines

  • P. Ghosh
  • S. K. Bhattacharya
Original Investigations

Abstract

The role of brain monoamines in the anticonvulsant action of Cannabis indica resin (CI), against maximal electroshock-induced seizures in albino rats, was investigated by using pharmacologic agents that influence brain monoamine activity. Delta-9-tetrahydrocannabinol content of cannabis resin was estimated to be 17%. The anticonvulsant action of CI (200 mg/kg, i.p.) was significantly inhibited after pretreatment with drugs that reduce brain serotonin activity but not by drugs that reduce brain catecholamine activity. Similarly, the anticonvulsant action of a subanticonvulsant dose (50 mg/kg, i.p.) of CI was potentiated by serotonin precursors but not by catecholamine precursors. Potentiation of the anticonvulsant action of CI by nialamide or by imipramine was inhibited after pretreatment with 5,6-dihydroxytrypt-amine. The results suggest that the anticonvulsant action of CI in the rat is serotonin- and not catecholamine-mediated.

Key words

Cannabis indica Anticonvulsant action Brain monoamines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Azzaro, A. J., Wenger, G. R., Craig, C. R., Stitzel, R. E.: Reserpine-induced alterations in brain amines and their relation to changes in the incidence of minimal electroshock seizures in mice. J. Pharmacol. Exp. Ther. 180, 558–568 (1972)Google Scholar
  2. Baumgarten, H. G., Bjorklund, A. L., Lachenmayer, L., Novin, A., Stenevi, U.: Longlasting selective depletion of brain serotonin by 5,6-dihydroxytryptamine. Acta Physiol. Scand. [Suppl.] 373, 1–16 (1971)Google Scholar
  3. Bhattacharya, S. K., Bose, R., Ghosh, P.: Anticonvulsant action of phenobarbitone in the rat. Role of brain monoamines. Materia Medica Polona (in press, 1978)Google Scholar
  4. Bhattacharya, S. K., Mukhopadhyay, S. N., Reddy, P. K. S. P., Das, P. K.: Role of brain monoamines in the anticonvulsant effect of imipramine in albino rats. Pharmacology 14, 428–434 (1976a)Google Scholar
  5. Bhattacharya, S. K., Reddy, P. K. S. P., Das, P. K.: Studies on the role of brain monoamines in the anticonvulsant action of diphenylhydantoin and nialamide-induced potentiation of diphenylhydantoin in albino rats. In: Drugs and central synaptic transmission, P. B. Bradley and B. N. Dhawan, ed., p. 155. London: Macmillan 1976b)Google Scholar
  6. Bose, B. C., Saifi, A. Q., Bhagwat, A. W.: Studies on the pharmacological actions of Cannabis indica (Linn). III. Arch. Int. Pharmacodyn. Ther. 147, 291–297 (1964)Google Scholar
  7. Boura, A. L. A., Green, A. F.: Adrenergic neurone blocking agents. Annu. Rev. Pharmacol. 5, 183–212 (1965)Google Scholar
  8. Buterbaugh, G. G.: A role for central serotonergic systems in the pattern and intensity of the convulsive response of rats to electroshock. Neuropharmacol. 16, 707–709 (1977)Google Scholar
  9. Carlsson, A., Lindqvist, M., Fuxe, K., Hokfelt, T.: Histochemical and biochemical effects of diethyldithiocarbamate on tissue catecholamines. J. Pharm. Pharmacol. 18, 60–62 (1966)Google Scholar
  10. Chadwick, D., Jenner, P., Reynolds, E. H.: Amines, anticonvulsants and epilepsy. Lancet 1975 I, 473–476Google Scholar
  11. Chen, G., Bohner, B. A.: A comparison of the anti-reserpine effects of certain centrally acting agents. Fed. Proc. 18, 376 (1959)Google Scholar
  12. Chen, G., Ensor, C. R., Bohner, B. A.: A facilitative action of reserpine on the central nervous system. Proc. Soc. Exp. Biol. Med. 86, 507–510 (1954)Google Scholar
  13. Fog, R.: On stereotypy and catalepsy. Studies on the effects of amphetamine and neuroleptics in rats. Acta Neurol. Scand. [Suppl.] 48, 1–66 (1972)Google Scholar
  14. Garriott, J. C., Forney, R. B., Richard, A. B.: Pharmacological properties of some cannabis related compounds. Arch. Int. Pharmacodyn. Ther. 171, 425–434 (1968)Google Scholar
  15. Izquierdo, I., Tannhauser, M.: The effect of cannabidiol on maximal electroshock seizures in rats. J. Pharm. Pharmacol. 25, 916–917 (1973)Google Scholar
  16. Jenner, P., Chadwick, D., Reynolds, E. H., Marsden, C. D.: Altered 5-HT metabolism with clonazepam, diazepam and diphenylhydantoin. J. Pharm. Pharmacol. 27, 707 (1975)Google Scholar
  17. Jonsson, G., Fuxe, K.: Effect of tetrahydrocannabinols on central monoamine neurones. Acta Pharmacol. Toxicol. 31, 6 (1972)Google Scholar
  18. Karler, R., Cely, W., Turkanis, S. A.: The anticonvulsant activity of cannabidiol and cannabinol. Life Sci. 13, 1527–1531 (1973)Google Scholar
  19. Karler, R., Cely, W., Turkanis, S. A.: Development of tolerance to an anticonvulsant effect of Δ-9-tetrahydrocannabinol and cannabinol. Res. Commun. Chem. Pathol. Pharmacol. 9, 23–29 (1974a)Google Scholar
  20. Karler, R., Cely, W., Turkanis, S. A.: Anticonvulsant action of Δ-9-tetrahydrocannabinol and its 11-hydroxy and 8 alpha, 11-hydroxy metabolites in the frog. Res. Commun. Chem. Pathol. Pharmacol. 9, 441–452 (1974b)Google Scholar
  21. Karler, R., Turkanis, S. A.: The development of tolerance and “reverse tolerance” to the anticonvulsant activity of Δ-9-tetrahydrocannabinol and cannabidiol. In: The pharmacology of marihuana, Vol. 1, M. C. Braude and S. Szara, eds., p. 299. New York: Raven 1976Google Scholar
  22. Kilbey, M. M., Moor, J. W. Jr., Hall, M.: 296-1 predatory aggression in the rat. Psychopharmacologia (Berl.) 31, 157–166 (1973)Google Scholar
  23. Kilian, M., Frey, H.-H.: Central monoamines and convulsive thresholds in mice and rats. Neuropharmacol. 12, 681–692 (1973)Google Scholar
  24. Koe, B. K., Weissman, A.: p-Chlorophenylalanine: a specific depletor of brain serotonin. J. Pharmacol. Exp. Ther. 154, 499–516 (1966)Google Scholar
  25. Loewe, S., Goodman, L. S.: Anticonvulsant action of marihuana substances. Fed. Proc. 6, 352 (1947)Google Scholar
  26. Maitre, L., Waldmeir, P. C., Bauman, P. A.: Effect of tetrahydrocannabinols on biosynthesis and utilisation of catecholamines in the rat brain. Biochem. Pharmacol. [Suppl.] 2, 845–850 (1974)Google Scholar
  27. Maynert, E. W., Marczynski, T. J., Browning, R. A.: The neurotransmitters in the epilepsies. In: Advances in neurology, Vol. 13, W. J. Friedlander, ed., p. 79. New York: Raven 1975Google Scholar
  28. Mayer, H., Frey, H. H.: Dependence of anticonvulsant drug action on central monoamines. Neuropharmacology 12, 939–947 (1973)Google Scholar
  29. Poddar, M. K., Biswas, B., Ghosh, J. J.: 296-2 and brain biogenic amines. In: Drugs and central synaptic transmission, P. B. Bradley and B. N. Dhawan, eds., p. 193. London: Macmillan 1976Google Scholar
  30. Prockop, D. J., Shore, P. A., Brodie, B. B.: Anticonvulsant properties of monoamine oxidase inhibitors. Ann. N.Y. Acad. Sci. 80, 643–650 (1959)Google Scholar
  31. Rowe, R. P., Bloom, B. M., P'an, S. W., Finger, K. F.: The pharmacologic characterisation of the antidepressant nialamide. Fed. Proc. 18, 376 (1959)Google Scholar
  32. Rudzik, A. D., Mennear, J. H.: The mechanism of action of anticonvulsants. I. Diphenylhydantoin. Life Sci. 4, 2373–2382 (1965)Google Scholar
  33. Schildkraut, J. J., Efron, D. H.: Effects of Δ-9-tetrahydrocannabinol on the metabolism of norepinephrine in rat brain. Psychopharmacolgia (Berl.) 20, 191–196 (1971)Google Scholar
  34. Shreshthrenia, K. S.: Sangram nighantu bhusanam, p. 226. Bombay: Shri Venkateshwar 1953Google Scholar
  35. Singh, D.: Unani Dravyagun Adarsh, Vol. 2, p. 550. Lucknow: Ayurvedic and Tibbi Academy 1974Google Scholar
  36. Singh, P. P., Das, P. K.: A heuropsychopharmacological study of Cannabis indica. Ind. J. Pharmacol. 7, 51–57 (1975)Google Scholar
  37. Sofia, R. D., Dixit, B. N., Barry, H.: Effects of Δ-9-tetrahydrocannabinol on serotonin metabolism in the rat brain. Life Sci. 10, 425–436 (1971)Google Scholar
  38. Spector, S.: Inhibitors of endogenous catecholamine biosynthesis. Pharmacol. Rev. 18, 599–609 (1966)Google Scholar
  39. Toman, J. E. P., Swinyard, E. A., Goodman, L. S.: Properties of maximal seizures and their alteration by anticonvulsant drugs and other agents. J. Neurophysiol. 9, 231–240 (1946)Google Scholar
  40. Ueki, S., Fujiwara, M.: Effects of changes in brain amine levels on Δ9-tetrahydrocannabinol-induced muricide in rats. Abstracts, 6th Int. Congr. Pharmacol., p. 505 (1975)Google Scholar
  41. Uretsky, N. J., Iversen, L. L.: Effects of 6-hydroxydopamine on noradrenaline-containing neurones in the rat brain. Nature 221, 557–559 (1969)Google Scholar
  42. Wada, J. A., Balzamo, E., Meldrum, B. S., Naquet, R.: Behavioural and electroencephalographic effects of L-5-hydroxytryptophan and DL-parachlorophenylalanine on epileptic Senegalese baboon (Papio papio). Electroencephal. Clin. Neurophysiol. 33, 520–526 (1972)Google Scholar
  43. Wenger, G. R., Stitzel, R. E., Craig, C. R.: Brain monoamines and minimal electroshock seizure threshold in mice. Neuropharmacology 12, 693–703 (1973)Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • P. Ghosh
    • 1
  • S. K. Bhattacharya
    • 1
  1. 1.Department of Pharmacology, Institute of Medical SciencesBanaras Hindu UniversityVaranasiIndia

Personalised recommendations